Interestingly, the CRAC channel inhibitor BTP2 or CM4620 was shown to significantly reduce the production of inflammatory cytokines (such as IFNγ, TNF, IL-17A, IL-13, and IL-4) from human intestinal T cells, B cells, ILCs and myeloid cells, and improve colon inflammation in a mouse model of IBD (Letizia et al., 2022). Here, TNF is linked to colitis.